BridgeBio Pharma (BBIO) Capital Expenditures (2018 - 2026)

BridgeBio Pharma has reported Capital Expenditures for 9 years, with the latest figure at $69000.0 in Q1 2026.

• Quarterly Capital Expenditures changed N/A year-over-year to $69000.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $1.2 million (up 380.29% YoY) and the FY2025 annual result came in at $1.1 million, up 293.19% from the prior year.
• Capital Expenditures slipped to $69000.0 in Q1 2026 per BBIO's latest filing, from $1.1 million in the prior quarter.
• Over five years, Capital Expenditures peaked at $4.8 million in Q4 2022 and troughed at -$3.2 million in Q3 2022.
• A 5-year average of $424400.0 and a median of $69000.0 in 2026 frame the typical range for Capital Expenditures.
• The sharpest annual moves came in 2024 and 2025: Capital Expenditures slumped 246.03% in 2024, then soared 21600.0% in 2025.
• Over 5 years, Capital Expenditures stood at $4.8 million in 2022, then tumbled by 101.93% to -$92000.0 in 2023, then surged by 105.43% to $5000.0 in 2024, then jumped by 21600.0% to $1.1 million in 2025, then tumbled by 93.64% to $69000.0 in 2026.
• According to Business Quant data, Capital Expenditures over the past three periods registered $69000.0, $1.1 million, and $12000.0 for Q1 2026, Q4 2025, and Q3 2025 respectively.